Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.

BACKGROUND: Drug eluting beads (DEB) are relatively new embolic agents that allow sustained release of chemotherapeutic agents in a localized fashion to the tumor. This technique is associated with reduced systemic side effects relative to systemic chemotherapy and an increase in the dose of antineo...

Full description

Bibliographic Details
Main Authors: Shilong Han, Xiaoping Zhang, Liling Zou, Chenhui Lu, Jun Zhang, Jue Li, Maoquan Li
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4118844?pdf=render
id doaj-ddd6a71c3a00488fb94b6ec6b33ce5b7
record_format Article
spelling doaj-ddd6a71c3a00488fb94b6ec6b33ce5b72020-11-24T21:42:52ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0198e10268610.1371/journal.pone.0102686Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.Shilong HanXiaoping ZhangLiling ZouChenhui LuJun ZhangJue LiMaoquan LiBACKGROUND: Drug eluting beads (DEB) are relatively new embolic agents that allow sustained release of chemotherapeutic agents in a localized fashion to the tumor. This technique is associated with reduced systemic side effects relative to systemic chemotherapy and an increase in the dose of antineoplastic agent delivered to the lesion. The meta-analysis was undertaken to assess the effectiveness of DEB-transcatheter arterial chemoembolization (TACE) in the management of hepatocellular cancer. METHODS: We searched the Web of Science, PubMed, EBSCO, EMBASE, the Wiley Library and Google Scholar for studies on DEB-TACE in the management of hepatocellular cancer from 1979 to April 2013. The risk of bias was assessed using RevMan 5 · 1. Random and fixed-effects meta-analytical models were used where indicated, and between-study heterogeneity was assessed. Disease control, complications and severe complications were recorded. RESULTS: Five studies met the selection criteria, three RCTs and two case-control studies, published from 2010 to 2012, included 217 patients in the DEB-TACE group and 237 in the conventional-TACE group. There was no significance over disease control (OR 2.27, 95% CI 0.78-6.63) with moderate between-study heterogeneity (χ(2) = 6.83, degrees of freedom [df] = 3; p<0.08; I(2) = 56%). Complications in both groups were assessed and no significant difference was observed (χ(2) = 6.34, degrees of freedom [df]  = 4; p<0.18; I(2)= 37%). Severe complications were also assessed and no significant difference was observed (χ(2) = 6.47, degrees of freedom [df]  = 4; p<0.17; I(2)= 38%). No publication bias relating to the above outcomes was detected by funnel plot. DEB-TACE benefited disease control without an increase in complications and severe complications.http://europepmc.org/articles/PMC4118844?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Shilong Han
Xiaoping Zhang
Liling Zou
Chenhui Lu
Jun Zhang
Jue Li
Maoquan Li
spellingShingle Shilong Han
Xiaoping Zhang
Liling Zou
Chenhui Lu
Jun Zhang
Jue Li
Maoquan Li
Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.
PLoS ONE
author_facet Shilong Han
Xiaoping Zhang
Liling Zou
Chenhui Lu
Jun Zhang
Jue Li
Maoquan Li
author_sort Shilong Han
title Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.
title_short Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.
title_full Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.
title_fullStr Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.
title_full_unstemmed Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.
title_sort does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? a meta-analysis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description BACKGROUND: Drug eluting beads (DEB) are relatively new embolic agents that allow sustained release of chemotherapeutic agents in a localized fashion to the tumor. This technique is associated with reduced systemic side effects relative to systemic chemotherapy and an increase in the dose of antineoplastic agent delivered to the lesion. The meta-analysis was undertaken to assess the effectiveness of DEB-transcatheter arterial chemoembolization (TACE) in the management of hepatocellular cancer. METHODS: We searched the Web of Science, PubMed, EBSCO, EMBASE, the Wiley Library and Google Scholar for studies on DEB-TACE in the management of hepatocellular cancer from 1979 to April 2013. The risk of bias was assessed using RevMan 5 · 1. Random and fixed-effects meta-analytical models were used where indicated, and between-study heterogeneity was assessed. Disease control, complications and severe complications were recorded. RESULTS: Five studies met the selection criteria, three RCTs and two case-control studies, published from 2010 to 2012, included 217 patients in the DEB-TACE group and 237 in the conventional-TACE group. There was no significance over disease control (OR 2.27, 95% CI 0.78-6.63) with moderate between-study heterogeneity (χ(2) = 6.83, degrees of freedom [df] = 3; p<0.08; I(2) = 56%). Complications in both groups were assessed and no significant difference was observed (χ(2) = 6.34, degrees of freedom [df]  = 4; p<0.18; I(2)= 37%). Severe complications were also assessed and no significant difference was observed (χ(2) = 6.47, degrees of freedom [df]  = 4; p<0.17; I(2)= 38%). No publication bias relating to the above outcomes was detected by funnel plot. DEB-TACE benefited disease control without an increase in complications and severe complications.
url http://europepmc.org/articles/PMC4118844?pdf=render
work_keys_str_mv AT shilonghan doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis
AT xiaopingzhang doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis
AT lilingzou doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis
AT chenhuilu doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis
AT junzhang doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis
AT jueli doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis
AT maoquanli doesdrugelutingbeadtranscatheterarterialchemoembolizationimprovethemanagementofpatientswithhepatocellularcarcinomaametaanalysis
_version_ 1725916729377292288